American Psychiatric Association 2019 Annual Meeting

The American Psychiatric Association 2019 Annual Meeting features a variety of innovative sessions and tracks focusing on changing the practice and perception of psychiatry. The meeting will take place from May 18-22, 2019, in San Francisco, California. The meeting provides opportunities to learn from renowned experts, discover ground-breaking technology, and understand new therapies. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
September 09, 2019
It’s crucial to have support from the numerous community settings that young people interact with so that they can feel understood and better manage their mental illness, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
August 30, 2019
Early intervention in potential cases of psychosis among young people hinges on multiple settings being aware of the early signs of the illness and able to link people to treatment, said Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
August 26, 2019
Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University, explained how large databases can help researchers understand the variety of psychotic illnesses, potentially leading to more personalized treatments.
August 20, 2019
When assessing young people for potential early psychosis, psychiatrists should keep in mind that reassurance is particularly important for this patient group, explained Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
August 15, 2019
Providers should treat patients with schizophrenia by thinking about them as people and understanding the full context of their lives, according to Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University.
August 09, 2019
Providers who treat young people with psychosis must navigate a host of issues unique to this population, including confidentiality and consent rules, the role of the family, and support from schools, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
August 04, 2019
Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
August 02, 2019
Data presented at the 175th Annual Meeting of the American Psychiatric Association (APA) support the potential of the investigational drug ALKS 3831 to provide the antipsychotic efficacy of olanzapine without the associated weight gain, said Adam Simmons, director of clinical program management, Alkermes. He also discussed the timing of when the data might be filed with the FDA.
July 26, 2019
Adam Simmons, director of clinical program management, Alkermes, explains that an investigational antipsychotic drug, ALKS 3831, provides the efficacy of olanzapine without the associated weight gain can provide benefits in the short and long term to payers and patients. Simmons spoke about data presented at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.
July 25, 2019
Increasing awareness of psychosis can help communities engage with patients on a human level and work together to improve, according to David Kingdon, MD, professor of mental health care delivery, University of Southampton.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.